BYSI supply chain intelligence for BeyondSpring Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BeyondSpring Inc. (BYSI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ASYMCHEM-LABORATORIES | ASYMCHEM-LABORATORIES | 90% | We outsource the production of the active pharmaceutical ingredient of Plinabulin to external service providers, Johnson Matthey Pharma Services (JMPS) and Asymchem Laboratories (Asymchem) |
| BASF-SE | BASF-SE | 90% | We rely on BASF SE as the sole supplier of the stabilizing agent, Kolliphor HS15, used in Plinabulin’s current formulation |
| PHARMACEUTICS-INTERNATIONAL-INC | PHARMACEUTICS-INTERNATIONAL-INC | 90% | and the production of the final drug formulation to Pharmaceutics International Inc. (Pii) and for contingency planning purposes, we have also established relationships with other contract manufactur… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LLY | Eli Lilly and Company | 92% | Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY grap… |
| LLY | Eli Lilly and Company | 72% | s based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for a specified period. The Hengrui Collaboration Agreement is within the scope of A… |
| CORPORATE-INFORMATION-BEYONDSPRING-INC | CORPORATE-INFORMATION-BEYONDSPRING-INC | 62% | al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three … |
| CT-CORPORATION | CT-CORPORATION | 62% | al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three … |
| JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD | 62% | the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L… |
| MAPFIL-INVESTMENT-LIMITED | MAPFIL-INVESTMENT-LIMITED | 62% | the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L… |
| PHARMACEUTICS-INTERNATIONAL-INC | PHARMACEUTICS-INTERNATIONAL-INC | 62% | al controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three … |
| SEED-TECHNOLOGY-LIMITED | SEED-TECHNOLOGY-LIMITED | 62% | so, with the grant of status as a 2017 National Science and Technology Major Project in China, or the 2017 Grant, Plinabulin has been included in the National Drug Priority Review List. We believe th… |
| WINNING-VIEW-INVESTMENT-LIMITED | WINNING-VIEW-INVESTMENT-LIMITED | 62% | the Company will sell and transfer to the Purchasers a total of 3,500,128 Shares, comprised of 1,750,064 Shares to Winning View Investment Limited, 583,355 Shares to FULL TECH CORPORATE DEVELOPMENT L… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BYSI-DEBT | Debt stack $246,000 | 90% | Market cache reports total debt of $246,000. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| BYSI-OWNER-DECHENG-CAPITAL-LLC | Decheng Capital LLC | 90% | 13F overlay lists Decheng Capital LLC as top holder; 23 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | 100.00 | 2 | |
| IVA | Inventiva S.A. | 100.00 | 2 | |
| ALEC | Alector, Inc. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 | |
| CRIS | Curis, Inc. | 100.00 | 2 | |
| INCY | Incyte Corporation | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| IMNM | Immunome, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 2 |